A detailed history of Tower Research Capital LLC (Trc) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,120 shares of ARWR stock, worth $179,025. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,120
Previous 27,091 66.34%
Holding current value
$179,025
Previous $704,000 75.0%
% of portfolio
0.0%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.36 - $29.54 $347,918 - $530,863
-17,971 Reduced 66.34%
9,120 $176,000
Q2 2024

Aug 13, 2024

BUY
$21.87 - $28.24 $516,285 - $666,661
23,607 Added 677.58%
27,091 $704,000
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $280,507 - $406,999
-10,309 Reduced 74.74%
3,484 $99,000
Q4 2023

Feb 13, 2024

BUY
$21.2 - $31.03 $151,601 - $221,895
7,151 Added 107.66%
13,793 $422,000
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $57,220 - $78,798
-2,184 Reduced 24.75%
6,642 $178,000
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $58,371 - $96,001
2,320 Added 35.66%
8,826 $314,000
Q1 2023

May 09, 2023

BUY
$23.68 - $38.51 $38,787 - $63,079
1,638 Added 33.65%
6,506 $165,000
Q4 2022

Feb 10, 2023

SELL
$28.0 - $40.56 $291,928 - $422,878
-10,426 Reduced 68.17%
4,868 $197,000
Q3 2022

Nov 10, 2022

BUY
$29.63 - $48.31 $212,891 - $347,107
7,185 Added 88.61%
15,294 $505,000
Q2 2022

Aug 15, 2022

BUY
$27.79 - $50.61 $146,508 - $266,815
5,272 Added 185.83%
8,109 $285,000
Q1 2022

May 12, 2022

SELL
$39.62 - $69.97 $221,713 - $391,552
-5,596 Reduced 66.36%
2,837 $130,000
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $304,449 - $432,434
-5,241 Reduced 38.33%
8,433 $559,000
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $298,088 - $433,805
5,106 Added 59.59%
13,674 $854,000
Q2 2021

Aug 16, 2021

SELL
$62.15 - $90.32 $422,992 - $614,717
-6,806 Reduced 44.27%
8,568 $709,000
Q1 2021

May 17, 2021

BUY
$61.35 - $90.47 $521,781 - $769,447
8,505 Added 123.82%
15,374 $1.02 Million
Q4 2020

Feb 16, 2021

BUY
$43.82 - $85.37 $82,644 - $161,007
1,886 Added 37.85%
6,869 $527,000
Q3 2020

Nov 16, 2020

SELL
$33.21 - $51.27 $679,941 - $1.05 Million
-20,474 Reduced 80.43%
4,983 $214,000
Q2 2020

Aug 13, 2020

BUY
$26.12 - $43.27 $664,936 - $1.1 Million
25,457 New
25,457 $1.1 Million
Q1 2020

May 15, 2020

SELL
$20.56 - $63.12 $95,706 - $293,823
-4,655 Closed
0 $0
Q4 2019

Feb 07, 2020

SELL
$28.14 - $73.01 $106,875 - $277,291
-3,798 Reduced 44.93%
4,655 $295,000
Q3 2019

Nov 05, 2019

BUY
$26.26 - $34.86 $211,445 - $280,692
8,052 Added 2007.98%
8,453 $238,000
Q2 2019

Aug 13, 2019

BUY
$17.43 - $28.82 $5,246 - $8,674
301 Added 301.0%
401 $11,000
Q1 2019

May 14, 2019

SELL
$12.05 - $20.18 $17,749 - $29,725
-1,473 Reduced 93.64%
100 $2,000
Q4 2018

Feb 14, 2019

BUY
$10.74 - $19.7 $5,724 - $10,500
533 Added 51.25%
1,573 $20,000
Q3 2018

Nov 13, 2018

BUY
$14.0 - $20.3 $14,560 - $21,112
1,040 New
1,040 $20,000
Q1 2018

May 15, 2018

SELL
$3.72 - $7.64 $91,939 - $188,822
-24,715 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$3.14 - $4.5 $77,605 - $111,217
24,715 New
24,715 $91,000
Q3 2017

Nov 14, 2017

BUY
$1.69 - $4.33 $0 - $0
0
0 $0

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.